Twist Bioscience (TWST) Launches High-Throughput Antibody Screening Service

What happened

Twist Bioscience launched Twist Express Screening Antibodies, a cell-free workflow that delivers purified full-length IgG and SPR binding characterization with turnaround starting at five days. The service offers quantities of 5–20 μg per antibody.

Confirmed

Global impact / market context

The new service line could bring in extra revenue and widen Twist's pipeline of pharmaceutical and biotech customers. Faster five-day turnaround may help it win business from slower contract research organizations, which are outside providers that run lab work for other companies.

Analyst inference

Twist is expanding into antibody production and characterization to capture demand from AI-driven drug discovery. The cell-free ALiCE expression method may lower cost of goods and raise throughput, while SPR binding data adds paid analysis that can increase revenue per customer.

Analyst inference

What to watch

1. Twist offers purified full-length IgG, scFv-Fc and VHH-Fc formats, which are antibody formats suitable for advancing candidates downstream, potentially improving conversion of screens into later programs. Confirmed
2. Watch for customer wins, revenue contribution disclosures or partnerships that would validate adoption and throughput at scale for the Express Screening Antibodies service. Proposed
3. Quantities of 5–20 μg per antibody suit rapid screens and allow more candidate testing; if demand grows, that could lift service revenue and absorb fixed costs. Analyst inference

Evidence

• Original source link unavailable